Halozyme Therapeutics Inc.

08/16/2022 | Press release | Distributed by Public on 08/16/2022 06:43

Halozyme Therapeutics, Inc. Announces Upsize and Pricing of Private Offering of $625 Million of Convertible Senior Notes due 2028 - Form 8-K